Breaking News Instant updates and real-time market news.

COST

Costco

$170.15

0.09 (0.05%)

, CSX

CSX

$49.56

2.63 (5.60%)

10:36
04/21/17
04/21
10:36
04/21/17
10:36

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Costco (COST) upgraded to Overweight from Equal Weight at Barclays with analyst Karen Short citing a survey by the firm where results showed analytically that Costco (COST) is "very protected" from Amazon (AMZN). 2. CSX (CSX) was upgraded to Buy from Hold at Aegis and to Outperform from Market Perform at Raymond James. 3. Gigamon (GIMO) upgraded to Buy from Hold at Stifel with analyst Patrick Newton citing valuation and his belief that the company has a number of potential positive catalysts, including the 100G upgrade cycle at T-Mobile (TMUS), in-line SSL decryption, and the potential for reduced competition from Ixia (XXIA). 4. Skechers (SKX) upgraded to Buy from Neutral at B. Riley with analyst Jeff Van Sinderen citing "strong" international growth and worldwide comps following the company's better than expected first quarter results. The analyst raised his price target for the shares to $32 from $28. 5. Quest Diagnostics (DGX) upgraded to Outperform from Market Perform at Raymond James with analyst Nicholas Jansen saying Quest has delivered two strait quarters of high single digit adjustment EBIT growth and sees room for sustained mid-to-high single digit growth driven by improved commercial execution, strengthening health system relationships and outreach deals, and invigorate programs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

COST

Costco

$170.15

0.09 (0.05%)

CSX

CSX

$49.56

2.63 (5.60%)

GIMO

Gigamon

$36.20

1.2 (3.43%)

SKX

Skechers

$25.76

-0.39 (-1.49%)

DGX

Quest Diagnostics

$104.94

0.91 (0.87%)

  • 24

    Apr

  • 03

    May

  • 05

    Jun

  • 12

    Jun

COST Costco
$170.15

0.09 (0.05%)

04/20/17
LEHM
04/20/17
UPGRADE
LEHM
Overweight
Costco upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Karen Short upgraded Costco to Overweight from Equal Weight, and raised her price target on shares to $185 from $170, citing a survey by the firm where results showed analytically that Costco (COST) is "very protected" from Amazon (AMZN).
04/20/17
LEHM
04/20/17
UPGRADE
LEHM
Overweight
Costco upgraded to Overweight from Equal Weight at Barclays
04/19/17
OPCO
04/19/17
NO CHANGE
OPCO
Oppenheimer bullish on Visa, MasterCard ahead of results
Oppenheimer analyst Glenn Greene reiterates Outperform ratings for MasterCard (MA) and Visa (V) and $120 and $95 price targets, respectively, heading into results. The analyst is encouraged by "solid" January intra-quarter volume growth, improving gas price trends, strong retail sales growth, and broadly positive card issuer trends. Further, Greene continues to believe that MasterCard and Visa are attractive at current levels, given their defensible market positions and strong long-term prospects. Nonetheless, he prefers Visa relative to MasterCard at present given the continuing U.S. volume boost from the Costco (COST)/USAA wins and JPMorgan Chase (JPM) Sapphire Reserve momentum, apparent conservative guidance, and Visa Europe accretion benefits.
04/21/17
LEHM
04/21/17
UPGRADE
Target $185
LEHM
Overweight
Costco upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Karen Short upgraded Costco Wholesale (COST) to Overweight after her survey of 800 customers indicated more than 80% of them go to Costco stores specifically for food. This suggests the company is "very protected" from Amazon (AMZN), Short tells investors in a research note. The analyst expects Costco's traffic to accelerate amid easing comparisons into the second half of the year. Short also sees the potential for a special dividend from a tax break on foreign cash repatriation. She raised her price target for the shares to $185 from $170.
CSX CSX
$49.56

2.63 (5.60%)

04/21/17
AGIS
04/21/17
UPGRADE
Target $64
AGIS
Buy
CSX upgraded to Buy from Hold at Aegis
Aegis analyst Jeffrey Kauffman upgraded CSX to Buy from Hold citing the increased clarity on CEO Hunter Harrison's improvement program following the company's Q1 results and FY guidance. Kauffman also increased his 2020 EPS forecast for CSX and raised his price target on the shares to $64 from $50.
04/21/17
UBSW
04/21/17
NO CHANGE
Target $60
UBSW
Buy
CSX upside potential attractive and shares should be bought, says UBS
UBS analyst Thomas Wadewitz noted CSX delivered a Q1 upside surprise. Also, given the earnings commentary, he believes the company's complex network of rails translates into a greater cost savings opportunity as the flow of traffic is simplified and number of work events/touches is reduced. Wadewitz reiterated his Buy rating and raised his price target to $60 from $57 on CSX shares.
04/21/17
04/21/17
UPGRADE
Target $55

Outperform
CSX at an inflection, upgraded to Outperform at Raymond James
As previously reported, Raymond James upgraded CSX to Outperform from Market Perform and established a $55 price target. Analyst Patrick Brown believes CSX is at an inflection point under new CEO Hunter Harrison and should see significant improvement in service, margins, and free cash flow. The analyst said the Q1 conference call provided detail on redesign plans and he is more confident that an improved network can create operational improvements. James expects the redesigned network will streamline operations and his optimization model suggest sub-60% OR is achievable.
04/21/17
SPHN
04/21/17
NO CHANGE
Target $58
SPHN
Overweight
CSX price target raised to $58 from $44 at Stephens
Stephens analyst Justin Long raised his price target for CSX to $58 from $44 following Q1 results. The analyst reiterates an Overweight rating on the shares.
GIMO Gigamon
$36.20

1.2 (3.43%)

04/20/17
STFL
04/20/17
UPGRADE
STFL
Buy
Gigamon upgraded to Buy from Hold at Stifel
04/21/17
STFL
04/21/17
UPGRADE
STFL
Buy
Gigamon upgraded on valuation, catalysts at Stifel
As noted earlier, Stifel upgraded Gigamon (GIMO) to Buy from Hold. Analyst Patrick Newton upgraded the stock based on valuation and his belief that the company has a number of potential positive catalysts, including the 100G upgrade cycle at T-Mobile (TMUS), in-line SSL decryption, and the potential for reduced competition from Ixia (XXIA). Target to $42 from $30.
03/17/17
JMPS
03/17/17
UPGRADE
Target $45
JMPS
Outperform
Gigamon upgraded to Outperform from Market Perform at JMP Securities
JMP Securities analyst Erik Suppiger upgraded Gigamon to Outperform saying his firm's channel checks indicate the company remains the clear leader for providing enterprise-grade security and that demand for network visibility remains healthy. The analyst has a $45 price target for the shares.
03/16/17
FBNS
03/16/17
INITIATION
Target $40
FBNS
Outperform
Gigamon initiated with an Outperform at FBN Securities
FBN Securities analyst Shebly Seyrafi started Gigamon with an Outperform rating and $40 target.
SKX Skechers
$25.76

-0.39 (-1.49%)

04/21/17
COWN
04/21/17
NO CHANGE
Target $35
COWN
Outperform
Skechers shares remain too cheap, says Cowen
Cowen analyst John Kernan said Skechers shares remain too cheap as he sees the balance of 2017 having a favorable setup versus the company's conservative guidance and the consensus view. Kernan reiterated his Outperform rating and $35 price target on Skechers shares.
04/21/17
RILY
04/21/17
UPGRADE
Target $32
RILY
Buy
Skechers upgraded to Buy from Neutral at B. Riley
B. Riley analyst Jeff Van Sinderen upgraded Skechers to Buy citing "strong" international growth and worldwide comps following the company's better than expected Q1 results. The analyst raised his price target for the shares to $32 from $28.
04/10/17
SUSQ
04/10/17
UPGRADE
SUSQ
Neutral
Skechers upgraded to Neutral from Negative at Susquehanna
Susquehanna analyst Sam Poser upgraded Skechers to Neutral with a $25 price target saying shares are fairly valued and reflect near-term challenges following recent share weakness.
04/10/17
04/10/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tesla (TSLA) upgraded to Overweight from Neutral at Piper Jaffray analyst Alexander Potter saying while Model 3 production headlines could create stock volatility, growth investors "can't afford to ignore this stock." Tesla's products have a "captivating impact on consumers and shareholders alike," an advantage that will be hard to replicate, the analyst adds. Potter is more convinced following meetings with management that Model 3 deliveries will begin in 2017. The analyst raised his price target for the shares to $368 from $223. 2. Amazon.com (AMZN) upgraded to Buy from Hold at Needham with analyst Kerry Rice saying he believes its established dominance in U.S. is sustainable with Prime, mobile penetration and third-party growth. Internationally, the analyst believes Europe provides the most near-term upside, while he views India as one of "the most exciting" long-term opportunities. Rice also believes AWS should continue to be a key driver for the company's bottom line growth. 3. Wells Fargo (WFC) upgraded to Neutral from Underweight at Piper Jaffray with analyst Kevin Barker saying headwinds from the account scandal are now embedded in consensus estimates and the stock's valuation. The analyst raised his price target for the shares to $55 from $52. 4. Ulta Beauty (ULTA) upgraded to Buy from Hold at Loop Capital with analyst Anthony Chukumba saying Ulta is the most compelling fundamental story in retail today. Chukumba feels the struggles of high-end department stores plays right into the company's hands. He also thinks Ulta is overdue for a stock split. 5. Skechers (SKX) upgraded to Neutral from Negative at Susquehanna with analyst Sam Poser saying shares are fairly valued and reflect near-term challenges following recent share weakness. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
DGX Quest Diagnostics
$104.94

0.91 (0.87%)

04/21/17
04/21/17
UPGRADE
Target $116

Outperform
Quest Diagnostics upgraded to Outperform on EBIT growth at Raymond James
As previously reported, Raymond James upgraded Quest Diagnostics to Outperform from Market Perform and established a $116 price target. Analyst Nicholas Jansen said Quest has delivered two strait quarters of high single digit adjustment EBIT growth and sees room for sustained mid-to-high single digit growth driven by improved commercial execution, strengthening health system relationships and outreach deals, and invigorate programs.
03/16/17
03/16/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Oracle (ORCL) was upgraded to Market Perform from Underperform at JMP Securities and to Overweight from Neutral at JPMorgan. 2. GoPro (GPRO) upgraded to Neutral from Sell at Citi with analyst Stanley Kovler saying the recent stabilization in revenue as well as the company's "significant" restructuring initiatives accelerate its path to profitability to 2017 from 2019. These developments should, at the very least, stave off the bear scenario for a few quarters, Kovler tells investors in a research note. He raised his price target for GoPro shares to $9 from $8. 2. TJX (TJX) upgraded to Conviction Buy from Buy at Goldman with analyst Matthew Fassler saying the company offers long-term secular growth along with near-term catalysts. The analyst expects TJX to grow market share at the expense of department stores. 4. Inovio (INO) upgraded to Buy from Hold at Maxim with analyst Jason McCarthy saying it has multiple earlier stage programs moving forward with more significant data points coming in 2017 while it moves closer to its pivotal study in cervical dysplasia. He notes that his model assumes that VGX-3100 is commercialized in 2021 for cervical dysplasia. 5. Quest Diagnostics (DGX) upgraded to Neutral from Underperform at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/21/17
RAJA
04/21/17
UPGRADE
RAJA
Outperform
Quest Diagnostics upgraded to Outperform from Market Perform at Raymond James
03/16/17
BOFA
03/16/17
UPGRADE
BOFA
Neutral
Quest Diagnostics upgraded to Neutral from Underperform at BofA/Merrill

TODAY'S FREE FLY STORIES

APC

Anadarko

$44.79

1.03 (2.35%)

16:13
09/20/17
09/20
16:13
09/20/17
16:13
Hot Stocks
Anadarko targets $1B of of share repurchases prior to year-end 2017 »

Speaking about the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

TBPH

Theravance Biopharma

$33.07

0.49 (1.50%)

, GSK

GlaxoSmithKline

$40.17

0.25 (0.63%)

16:12
09/20/17
09/20
16:12
09/20/17
16:12
Hot Stocks
GlaxoSmithKline and Innoviva report positive Phase 3 results of Treleg Ellipta »

Theravance Biopharma…

TBPH

Theravance Biopharma

$33.07

0.49 (1.50%)

GSK

GlaxoSmithKline

$40.17

0.25 (0.63%)

INVA

Innoviva

$13.59

0.08 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

  • 24

    Oct

APC

Anadarko

$44.79

1.025 (2.34%)

16:11
09/20/17
09/20
16:11
09/20/17
16:11
Hot Stocks
Anadarko announces $2.5B share repurchase program »

Anadarko Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

QUAD

Quad/Graphics

$20.16

0.33 (1.66%)

16:11
09/20/17
09/20
16:11
09/20/17
16:11
Hot Stocks
Quad/Graphics awarded $450M contract to print all Bluestem catalogs »

Quad/Graphics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

MLHR

Herman Miller

16:11
09/20/17
09/20
16:11
09/20/17
16:11
Hot Stocks
Breaking Hot Stocks news story on Herman Miller »

Herman Miller reports Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

STBZ

State Bank Financial

$27.79

0.45 (1.65%)

16:08
09/20/17
09/20
16:08
09/20/17
16:08
Hot Stocks
FDIC approves State Bank Financial, AloStar merger transaction »

State Bank Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLHR

Herman Miller

16:07
09/20/17
09/20
16:07
09/20/17
16:07
Hot Stocks
Herman Miller CEO says 'encouraged by the strong level of demand' »

Brian Walker, CEO,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

ARCC

Ares Capital

$15.85

0.035 (0.22%)

16:07
09/20/17
09/20
16:07
09/20/17
16:07
Initiation
Ares Capital initiated  »

Ares Capital initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLHR

Herman Miller

16:06
09/20/17
09/20
16:06
09/20/17
16:06
Earnings
Herman Miller sees Q2 EPS 55c-61c, consensus 56c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

MLHR

Herman Miller

16:05
09/20/17
09/20
16:05
09/20/17
16:05
Earnings
Herman Miller reports Q1 adjusted EPS 57c, consensus 57c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

MDXG

MiMedx

$12.34

-0.82 (-6.23%)

16:05
09/20/17
09/20
16:05
09/20/17
16:05
Hot Stocks
MiMedx responds to two "deceptive short seller articles" »

MiMedx Group responded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

LUNA

Luna Innovations

$1.64

0.05 (3.14%)

16:05
09/20/17
09/20
16:05
09/20/17
16:05
Hot Stocks
Luna Innovations announces stock repurchase program »

Luna Innovations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AERI

Aerie Pharmaceuticals

$53.40

-5.2 (-8.87%)

16:03
09/20/17
09/20
16:03
09/20/17
16:03
Hot Stocks
Aerie announces FDA Advisory Committee meeting for Rhopressa 0.02% »

Aerie Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 28

    Feb

AMD

AMD

$13.12

0.04 (0.31%)

, TSLA

Tesla

$375.10

-9.9 (-2.57%)

15:57
09/20/17
09/20
15:57
09/20/17
15:57
Periodicals
Tesla working with AMD on self-driving car AI chip, CNBC says »

Tesla (TSLA) is using AMD…

AMD

AMD

$13.12

0.04 (0.31%)

TSLA

Tesla

$375.10

-9.9 (-2.57%)

NVDA

Nvidia

$187.35

-0.2 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

AMD

AMD

$13.12

0.04 (0.31%)

, TSLA

Tesla

$375.10

-9.9 (-2.57%)

15:54
09/20/17
09/20
15:54
09/20/17
15:54
Periodicals
Breaking Periodicals news story on AMD, Tesla »

Tesla working with AMD on…

AMD

AMD

$13.12

0.04 (0.31%)

TSLA

Tesla

$375.10

-9.9 (-2.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

15:50
09/20/17
09/20
15:50
09/20/17
15:50
General news
More from Yellen: »

More from Yellen: FOMC…

VIX

Volatility Index S&P 500 Options

15:40
09/20/17
09/20
15:40
09/20/17
15:40
Options
Active trading in VIX calls as players replace expiring positions »

Active trading in VIX…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:35
09/20/17
09/20
15:35
09/20/17
15:35
General news
Yellen on the FRB »

Yellen on the FRB: she is…

DMPI

DelMar Pharmaceuticals

$1.12

0.0294 (2.70%)

15:33
09/20/17
09/20
15:33
09/20/17
15:33
Syndicate
DelMar Pharmaceuticals announces $10M registered direct offering at-the-market »

DelMar Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$47.94

0.27 (0.57%)

15:30
09/20/17
09/20
15:30
09/20/17
15:30
Options
Far downside put buying in Morgan Stanley »

Far downside put buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 02

    Oct

  • 22

    Oct

JWN

Nordstrom

$46.13

-0.09 (-0.19%)

15:25
09/20/17
09/20
15:25
09/20/17
15:25
Conference/Events
Nordstrom management to meet with Wolfe Research »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BG

Bunge

$71.38

-1.1 (-1.52%)

15:25
09/20/17
09/20
15:25
09/20/17
15:25
Options
Bunge call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:25
09/20/17
09/20
15:25
09/20/17
15:25
General news
More from Yellen on inflation »

More from Yellen on…

WFC

Wells Fargo

$53.95

0.591 (1.11%)

15:22
09/20/17
09/20
15:22
09/20/17
15:22
Hot Stocks
Chair Yellen calls Wells Fargo actions 'unacceptable' »

Fed Chair Janet Yellen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 12

    Oct

  • 22

    Oct

  • 29

    Nov

  • 15

    Jan

15:20
09/20/17
09/20
15:20
09/20/17
15:20
General news
The FOMC dot-plot projections »

The FOMC dot-plot…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.